Fight Aging! Newsletter, August 7th 2023
In conclusion, here, we demonstrate a novel mechanism for ESC-EVs to protect cells from senescence. However, whether ESC-EVs rejuvenate aged mice via miR-15b-5p and miR-290a-5p remains unknown. Next, we plan to use miR-15b-5p and miR-290a-5p antagonists while treating aged mice with ESC-EVs to further investigate the mechanism by which ESC-EVs resist aging in vivo. « Back to Top Fatty Acid Metabolism as a Commonality in Different Approaches to Slowing Aging https://www.fightaging.org/archives/2023/08/fatty-acid-metabolism-as-a-commonality-in-different-approaches-to-slowing-aging/ It seem...
Source: Fight Aging! - August 6, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Fatty Acid Metabolism as a Commonality in Different Approaches to Slowing Aging
In this study, we report systemic changes in the molecular regulation of biological processes under multiple lifespan-extending interventions, by jointly leveraging systems-level analyses on two mouse liver proteomic datasets, which were generated in the NIA Longevity Consortium, and a previously published mouse liver transcriptomic dataset. Differential Rank Conservation (DIRAC) analyses of mouse liver proteomics and transcriptomics data show that mechanistically distinct lifespan-extending interventions (acarbose, 17α-estradiol, rapamycin, and calorie restriction) generally tighten the regulation of biological modules. ...
Source: Fight Aging! - August 2, 2023 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs

Fight Aging! Newsletter, October 10th 2022
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - October 9, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Interventions Testing Program Results for Rapamycin and Arcabose in Combination
The Interventions Testing Program (ITP) at the National Institute on Aging (NIA) performs rigorous, expensive assessments of the ability of various (usually pharmaceutical) interventions to slow aging in mice. Conducting a study with rigor in this context means the use of large numbers of mice spread across multiple facilities, with careful control of the environment in order to minimize both known and unknown confounding factors in life span studies. Most of the interventions tested over the past twenty years of the ITP, on the basis of earlier studies suggesting that they may slow aging, in fact fail to extend life in mi...
Source: Fight Aging! - October 6, 2022 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs

Fight Aging! Newsletter, September 5th 2022
Conclusion Coupled with the animal data, and the existing human trial data for safety, the results here suggests that someone should run a formal, controlled trial of flagellin immunization in older people, 65 and over. The goal would be to see whether (a) this sort of outcome holds up in a larger group of people, and (b) there is a meaningful impact on chronic inflammation and other parameters of health that are known to be affected by the aging of the gut microbiome. The most interesting part of the data is perhaps the decline in microbial diversity, when considered against the gains elsewhere. Microbial dive...
Source: Fight Aging! - September 4, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Searching for Age-Slowing Drugs in the Antidiabetic Portfolio
Data for the ability of metformin to slow aging has researchers looking at other antidiabetic drugs these days, even given that the evidence for metformin to have a meaningful impact on aging in non-diabetic animals is not great, very mixed, and even the human data for a modest addition of a few years in type 2 diabetes patients is most likely not as good as the impact of exercise and control of weight. Still, repurposing drugs to produce modest effects in a different condition has long been a going concern; regulators make it so hard to develop new drugs that it makes economic sense to repurpose existing drugs, even when ...
Source: Fight Aging! - August 31, 2022 Category: Research Authors: Reason Tags: Daily News Source Type: blogs

Type 2 diabetes: Which medication is best for me?
If you are living with type 2 diabetes, you certainly are not alone. One in 10 people in the US has diabetes, according to the CDC. However, despite considerable progress in diabetes treatment over the past 20 years, fewer than half of those with diabetes actually reach their target blood sugar goal. In part, this may be because doctors can be slow to make changes to a patient’s treatment plan, even when a patient’s treatment goals are not being met. One reason for this may be the overwhelming number of medications currently available. And yet, waiting too long to adjust treatment for type 2 diabetes can have long-last...
Source: Harvard Health Blog - November 5, 2020 Category: Consumer Health News Authors: Samar Hafida, MD Tags: Diabetes Drugs and Supplements Source Type: blogs

Canagliflozin protects Heart and Kidneys – CREDENCE Trial
Canagliflozin protects Heart and Kidneys – CREDENCE Trial Canagliflozin is sodium–glucose cotransporter 2 (SGLT2) inhibitor used in the treatment of type 2 diabetes mellitus. CREDENCE Trial [1] has shown that Canagliflozin provides both cardiovascular and renal protection in patients with type 2 diabetes mellitus. CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) trial was a double blind randomized trial comparing Canagliflozin 100 mg daily with placebo in type 2 diabetes with albuminuria and chronic kidney disease. They were also treated with renin–angiotensin...
Source: Cardiophile MD - April 15, 2019 Category: Cardiology Authors: Prof. Dr. Johnson Francis Tags: Cardiology Source Type: blogs

Fight Aging! Newsletter, March 18th 2019
This study provides a possible reason why genes carrying health risks have persisted in human populations. The second found evidence for multiple variants in genes related to ageing that exhibited antagonistic pleiotropic effects. They found higher risk allele frequencies with large effect sizes for late-onset diseases (relative to early-onset diseases) and an excess of variants with antagonistic effects expressed through early and late life diseases. There also exists other recent tangible evidence of antagonistic pleiotropy in specific human genes. The SPATA31 gene has been found under strong positive genomic sele...
Source: Fight Aging! - March 17, 2019 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

SGLT-2 Inhibitors as Calorie Restriction Mimetics
SGLT-2 inhibitors, or gliflozins, are a newer and still expensive class of anti-diabetic drug. They work by interfering in the trafficking of glucose, preventing the kidney from reclaiming glucose and introducing it back into the bloodstream. The glucose is instead excreted. Analogously to metformin, another anti-diabetic drug, it is proposed that inhibition of SGLT-2 in some ways mimic the effects of calorie restriction, triggering beneficial cellular housekeeping mechanisms that usually only turn on during periods of fasting or low calorie intake. Size of effect and degree of side-effects are always the questions in thes...
Source: Fight Aging! - March 14, 2019 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs

Questions Raised About Invokana Label Expansion For CV Risk Reduction
It hasn’t received a lot of media attention but on Tuesday the FDA approved an expansion of the canagliflozin (Invokana, Janssen) label to include a reduction in the risk of heart attack, stroke, or CV death in adults with type 2 diabetes and established CV disease. Canagliflozin, an oral SGLT2 inhibitor, thus becomes the third...Click here to continue reading... (Source: CardioBrief)
Source: CardioBrief - November 1, 2018 Category: Cardiology Authors: Larry Husten Tags: Diabetes People, Places & Events Policy & Ethics CVOT Invokana Source Type: blogs

Join the Undoctored Revolution
Let’s take back control over personal health. Share this to expose healthcare for the corrupt enterprise it is. Imagine that you receive a letter in the mail stating “In order to retain your right to freedom of speech, you will be billed $10,000 per year every year for the rest of your life.” You would be—-understandably-—outraged. Freedom of speech in America is precious, something Americans have waged wars to defend, something we now view as a basic right, no financial price required to maintain it. It should be free and available to everyone regardless of religion, color, political leanings, or income. ...
Source: Wheat Belly Blog - February 9, 2018 Category: Cardiology Authors: Dr. Davis Tags: Undoctored Wheat Belly Lifestyle diy health Dr. Davis grain-free healthcare Source Type: blogs

How does SGLT2 inhibition improve heart failure?
How does Sodium Glucose Cotransporter-2 (SGLT2) inhibition improve heart failure? Different ways by which SGLT2 inhibition can improve heart failure are: Natriuresis Osmotic diuresis These in turn leads to reduction of plasma volume and preload. An associated decrease in blood pressure, after load and arterial stiffness follows. Reduction in afterload can improve subendocardial blood flow as well. SGLT2 inhibitors are a new class of oral hypoglycemic agents. EMPA-REG OUTCOME trial with Empagliflozin (Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) and CANVAS trial (Canagliflozin Cardiovascular As...
Source: Cardiophile MD - October 27, 2017 Category: Cardiology Authors: Johnson Francis Tags: General Cardiology Source Type: blogs

Health should be FREE
Imagine that you receive a notice in the mail stating “In order to maintain your freedom of speech, you will be billed $10,000 per year.” You would be—understandably—outraged. Freedom of speech in America is precious, something Americans have fought wars to defend. We view free speech as a basic right, no big check to write in order to maintain it. It should be free and available to everyone regardless of religion, color, political leanings, or income. I believe that same principle should apply to health. Being healthy means living free of common chronic health conditions such as high cholesterol, high blood sugars...
Source: Wheat Belly Blog - March 31, 2017 Category: Cardiology Authors: Dr. Davis Tags: Undoctored crowd wisdom health free Healthcare System predatory wheat belly Source Type: blogs

Money in Medicine Report
In late November, a report was released that focused on money in medicine, and the top thirty drugs that were associated with pharmaceutical industry payments to Oregon doctors. Interestingly, the top thirty list did not include many drugs that are known to be household names. For example, the top three drugs – Bydureon, Invokana, and Toujeo – are prescribed for diabetes, a highly prevalent disease in America. Three others on the list are prescribed for multiple sclerosis, a debilitating condition that is incurable and can be hard to live with. Hysingla, an abuse-deterrent hydrocodone pill, is also high on the list. A...
Source: Policy and Medicine - December 5, 2016 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs